Page last updated: 2024-09-04

moxifloxacin and Cardiac Diseases

moxifloxacin has been researched along with Cardiac Diseases in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kenward, MG; Roger, JH	1
Arvis, P; Fritsch, A; Haverkamp, W; Kruesmann, F; van Veenhuyzen, D	1

Other Studies

2 other study(ies) available for moxifloxacin and Cardiac Diseases

Article	Year
The use of baseline covariates in crossover studies. Biostatistics (Oxford, England), 2010, Volume: 11, Issue:1 Topics: Algorithms; Analysis of Variance; Antihypertensive Agents; Aza Compounds; Bias; Blood Pressure; Bronchial Hyperreactivity; Controlled Clinical Trials as Topic; Cross-Over Studies; Electrocardiography; Epidemiologic Research Design; Fluoroquinolones; Forced Expiratory Volume; Heart Diseases; Humans; Hypertension; Likelihood Functions; Models, Statistical; Moxifloxacin; Nitric Oxide; Pain; Quinolines; Statistical Distributions	2010
Update on the cardiac safety of moxifloxacin. Current drug safety, 2012, Volume: 7, Issue:2 Topics: Administration, Oral; Age Factors; Aged; Animals; Anti-Infective Agents; Aza Compounds; Drug Labeling; Female; Fluoroquinolones; Heart Diseases; Humans; Infusions, Intravenous; Long QT Syndrome; Male; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors	2012

Article

Year

The use of baseline covariates in crossover studies.

Biostatistics (Oxford, England), 2010, Volume: 11, Issue:1

Topics: Algorithms; Analysis of Variance; Antihypertensive Agents; Aza Compounds; Bias; Blood Pressure; Bronchial Hyperreactivity; Controlled Clinical Trials as Topic; Cross-Over Studies; Electrocardiography; Epidemiologic Research Design; Fluoroquinolones; Forced Expiratory Volume; Heart Diseases; Humans; Hypertension; Likelihood Functions; Models, Statistical; Moxifloxacin; Nitric Oxide; Pain; Quinolines; Statistical Distributions

2010

Update on the cardiac safety of moxifloxacin.

Current drug safety, 2012, Volume: 7, Issue:2

Topics: Administration, Oral; Age Factors; Aged; Animals; Anti-Infective Agents; Aza Compounds; Drug Labeling; Female; Fluoroquinolones; Heart Diseases; Humans; Infusions, Intravenous; Long QT Syndrome; Male; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Risk Factors; Sex Factors

2012